| |
PSA progression during initial HT (n=27)
|
Patient population without PSA progression (n=305)
|
|---|
|
patient age/years median (range) mean±SD
|
74 (45–81) 72±8
|
71 (52–84) 71±6
|
|
follow-up period/months† median (range) mean±SD
|
48 (11–113) 50±23
|
69 (2–115) 66±18
|
|
T stage >2a†
|
74%
|
25%
|
|
Gleason score >6†
|
48%
|
19%
|
|
primary PSA /ng/ml† median (range) mean±SD
|
16(4–150) 31±37
|
10(1–300) 16±25
|
|
low risk patients*†
|
7%
|
37%
|
|
intermediate risk patients**†
|
7%
|
28%
|
|
high risk patients***†
|
85%
|
35%
|
|
initial HT (before RT)†
|
100%
|
40%
|
|
initial HT >6months†
|
78%
|
13%
|
|
HDR-BT
|
19%
|
22%
|
|
EBRT
|
81%
|
78%
|
- * no risk factors: PSA<10ng/ml; Gleason score<7; cT-stage<2b.
- ** one risk factor: PSA 10-20ng/ml or Gleason score=7 or cT-stage=2b/c.
- *** two risk facors or PSA>20ng/ml or Gleason score>7 or cT-stage>2b/c.
- †statistically significant difference (p<0.01).
- Abbreviations: HDR-BT = high-dose rate brachytherapy; EBRT = external beam radiotherapy; SD = standard deviation; PSA = prostate-specific antigen; HT = hormonal therapy.
